ECSP19001438A - Anticuerpos anti_ige - Google Patents

Anticuerpos anti_ige

Info

Publication number
ECSP19001438A
ECSP19001438A ECSENADI20191438A ECDI201901438A ECSP19001438A EC SP19001438 A ECSP19001438 A EC SP19001438A EC SENADI20191438 A ECSENADI20191438 A EC SENADI20191438A EC DI201901438 A ECDI201901438 A EC DI201901438A EC SP19001438 A ECSP19001438 A EC SP19001438A
Authority
EC
Ecuador
Prior art keywords
ige
improved
antigen
binding agents
antibodies
Prior art date
Application number
ECSENADI20191438A
Other languages
English (en)
Inventor
Alistair James Henry
Brian John Sutton
Ralph Adams
Marta Katarzyna Westwood
James Michael Mcdonnell
Xiaofeng Liu
Thomas Allen Ceska
Anna Marie Davies
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of ECSP19001438A publication Critical patent/ECSP19001438A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)

Abstract

La presente invención se relaciona con el área de anti-cuerpos anti_IgE y agentes de unión a antígeno mejorados y sus composiciones dirigidos a IgE, por ejemplo: para su uso en el tratamiento de trastornos ocasionados por IgE (como por ejemplo respuestas alérgicas o ciertas respuestas autoinmunitarias); y, en particular, en trastornos ocasionados por la actuación recíproca de IgE con el receptor de FcεRI. En particular, esta invención se relaciona con anticuerpos anti_IgE y agentes de unión a antígeno mejorados relacionados con mutantes novedosos de omalizumab (Xolair®). Los anticuerpos anti_IgE y agentes de unión a antígeno mejorados de la invención pueden tener una afinidad mejorada para IgE y/o una actuación recíproca mejorada con el dominio Cε2 de IgE y/o un epítopo modi-ficado mejorado en IgE (por ejemplo en el cual participa adicionalmente el dominio Cε2 de IgE) y/o la capacidad para disociar IgE del receptor de FcεRI por ejemplo a concentraciones relevantes desde el punto de vista farma-céutico. En un aspecto, se revelan tratamientos mejorados o novedosos para trastornos mediados por IgE en los cuales IgE es seleccionada como meta (por ejemplo IgE libre y/o IgE en un complejo con el receptor de FcεRI).
ECSENADI20191438A 2016-06-10 2019-01-08 Anticuerpos anti_ige ECSP19001438A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1610198.2A GB201610198D0 (en) 2016-06-10 2016-06-10 Anti-ige antibodies
GBGB1702435.7A GB201702435D0 (en) 2016-06-10 2017-02-15 Anti-ige antibodies

Publications (1)

Publication Number Publication Date
ECSP19001438A true ECSP19001438A (es) 2019-01-31

Family

ID=56894897

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI20191438A ECSP19001438A (es) 2016-06-10 2019-01-08 Anticuerpos anti_ige

Country Status (26)

Country Link
US (3) US11214627B2 (es)
EP (1) EP3468995A1 (es)
JP (3) JP7164439B2 (es)
KR (1) KR102456813B1 (es)
CN (1) CN109379892B (es)
AR (1) AR108707A1 (es)
AU (1) AU2017277600B2 (es)
BR (1) BR112018074838A2 (es)
CA (1) CA3027120A1 (es)
CL (2) CL2018003556A1 (es)
CO (1) CO2018013006A2 (es)
EA (1) EA201990004A1 (es)
EC (1) ECSP19001438A (es)
GB (2) GB201610198D0 (es)
IL (3) IL263452B2 (es)
MA (1) MA45231A (es)
MX (1) MX2018014761A (es)
PE (1) PE20190212A1 (es)
PH (1) PH12018502574A1 (es)
SG (1) SG11201810199WA (es)
TN (1) TN2018000423A1 (es)
TW (1) TW201802114A (es)
UA (1) UA126468C2 (es)
UY (1) UY37290A (es)
WO (1) WO2017211928A1 (es)
ZA (2) ZA201807822B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201610198D0 (en) * 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
HUE065861T2 (hu) * 2016-08-26 2024-06-28 Sanofi Sa Szelektív könnyûlánc-párosítást elõsegítõ multispecifikus antitestek
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
EP3774925A1 (en) 2018-04-13 2021-02-17 Institut national de la santé et de la recherche médicale (INSERM) Fc-engineered anti-human ige antibodies and methods of use
JP7518821B2 (ja) * 2018-10-16 2024-07-18 ユーシービー バイオファルマ エスアールエル 重症筋無力症の治療方法
GB2589049C (en) * 2019-04-11 2024-02-21 argenx BV Anti-IgE antibodies
EP3998286A4 (en) * 2019-07-11 2023-04-26 Wuhan Yzy Biopharma Co., Ltd. QUAD VALUE SYMMETRIC BISPECIFIC ANTIBODIES
US12435127B2 (en) 2019-09-25 2025-10-07 The General Hospital Corporation Therapeutic neutralization antibodies for the treatment of peanut allergy
AU2020358898B2 (en) * 2019-10-01 2025-10-16 Epsilogen Ltd Hybrid antibody
TW202128748A (zh) 2020-01-24 2021-08-01 日商西斯美股份有限公司 提升抗體對抗原之親和性的方法及其用途
CN113372450A (zh) * 2020-03-10 2021-09-10 北京万华生物工程有限公司 IgE嵌合性双特异性抗体制备及应用
WO2021225980A1 (en) * 2020-05-04 2021-11-11 Dna-Seq, Inc. Methods and systems for determination of an effective therapeutic regimen and drug discovery
WO2021250546A1 (en) 2020-06-09 2021-12-16 University Of Washington Micrornas as predictors of response to anti-ige therapies in chronic spontaneous urticaria
EP4180454A4 (en) * 2020-07-10 2024-10-02 Shanghai Jemincare Pharmaceuticals Co., Ltd. Anti-ige engineered antibody and application thereof
CN111875706B (zh) * 2020-07-16 2021-03-30 广州康盛生物科技股份有限公司 一种抗人IgE蛋白的单域抗体及其应用
WO2022045865A1 (ko) * 2020-08-31 2022-03-03 (주)메디톡스 항-ｖｅｇｆ 육량체 항체, 및 이를 포함하는 조성물
WO2022061236A1 (en) * 2020-09-21 2022-03-24 The Board Of Trustees Of The Leland Stanford Junior University High affinity anti-ige antibodies
US20230122862A1 (en) * 2021-10-12 2023-04-20 United BioPharma, Inc. Treatment of ige-mediated diseases
US20260035484A1 (en) * 2021-10-29 2026-02-05 Longbio Pharma (Suzhou) Co., Ltd. Isolated antigen binding protein and use thereof
CN114028569B (zh) * 2021-12-20 2023-04-28 中国医学科学院基础医学研究所 免疫球蛋白IgE在诊断和/或治疗高血压中的用途
CN114504644B (zh) * 2021-12-24 2024-02-13 北京大学第一医院 抗IgE抗体在用于治疗腺样体肥大中的应用
IL318098A (en) * 2022-07-01 2025-02-01 Alk Abell? As IGE-FCER pushers
US20240182599A1 (en) * 2022-10-07 2024-06-06 Abwiz Bio, Inc. Anti-ige antibodies
CN116143932B (zh) * 2022-12-07 2025-02-11 南开大学 一种针对IgE的抗体或其抗原结合片段以及Fc变体
CN118725128B (zh) * 2023-03-28 2025-09-16 东莞市朋志生物科技有限公司 抗IgE抗体、检测IgE的试剂和试剂盒
KR102933992B1 (ko) 2023-05-10 2026-03-05 대한민국 (식품의약품안전처장) 아나필락시스 예측용 바이오마커
CN116754773B (zh) * 2023-05-15 2024-06-07 江南大学 一种免疫球蛋白e的检测试剂盒
CA3237624A1 (en) * 2023-07-28 2025-04-24 Genentech, Inc. NEW USES FOR OMALIZUMAB
CN119490595B (zh) * 2023-08-15 2025-11-18 东莞市朋志生物科技有限公司 一种抗免疫球蛋白e的抗体及其应用
WO2025122927A1 (en) * 2023-12-06 2025-06-12 Integral Molecular, Inc. Antibodies directed to claudin 18.2, including bispecific formats thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
US20250353928A1 (en) * 2024-05-17 2025-11-20 Excellergy, Inc. Antibodies and antibody fragments that bind ige
CN119841957B (zh) * 2025-01-13 2025-08-05 上海领检科技有限公司 一种抗人IgE抗体及其用途

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
DE3587814T2 (de) 1985-03-30 1994-11-10 Marc Ballivet Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren.
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DE3600905A1 (de) 1986-01-15 1987-07-16 Ant Nachrichtentech Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
EP0478627A4 (en) 1989-05-16 1992-08-19 William D. Huse Co-expression of heteromeric receptors
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
EP1260521B1 (en) 1991-08-14 2007-11-21 Genentech Inc. Immunoglobulin variants for specific Fc epsilon receptors
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
WO1993011794A1 (en) 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
ZA966075B (en) 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
ZA971607B (en) * 1996-03-12 1998-08-25 Univ Johns Hopkins Methods of treatment of allergic diseases
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US6172213B1 (en) 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
CN1289253A (zh) * 1998-01-29 2001-03-28 泰诺士公司 以lgE拮抗剂治疗特应性皮炎
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
WO2000072879A1 (en) * 1999-05-26 2000-12-07 Tanox, Inc. TREATING ALLERGIC DISEASES WITH IMMUNOTHERAPY AND IgE ANTAGONISTS
US20030190598A1 (en) 2000-05-26 2003-10-09 Jasmid Tanha Single-domain antigen-binding antibody fragments derived from llama antibodies
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
GB0129105D0 (en) 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
WO2004051268A1 (en) 2002-12-03 2004-06-17 Celltech R & D Limited Assay for identifying antibody producing cells
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
PT1644412E (pt) 2003-07-01 2015-12-23 Ucb Biopharma Sprl Fragmentos de anticorpos fab modificados
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
GB0502358D0 (en) 2005-02-04 2005-03-16 Novartis Ag Organic compounds
KR20140053410A (ko) 2005-08-19 2014-05-07 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
UY30994A1 (es) * 2007-04-02 2008-11-28 Amgen Fremont Inc Anticuerpos anti-ige
EP2155238B1 (en) * 2007-06-05 2016-04-06 Yale University Antibody against d4 domain of the kit receptor and use thereor
EP2535350B1 (en) 2007-09-26 2018-01-24 UCB Biopharma SPRL Dual specificity antibody fusions
MX2010006735A (es) 2007-12-21 2010-09-30 Medimmune Ltd Miembros de union para receptor alfa de interleucina-4 (il-4ra) - 173.
JP5470817B2 (ja) 2008-03-10 2014-04-16 日産自動車株式会社 電池用電極およびこれを用いた電池、並びにその製造方法
CN101230103B (zh) * 2008-03-25 2011-09-07 中国医药集团总公司四川抗菌素工业研究所 一全人源重组抗-IgE抗体
US10407513B2 (en) 2008-09-26 2019-09-10 Ucb Biopharma Sprl Biological products
WO2011030107A1 (en) 2009-09-10 2011-03-17 Ucb Pharma S.A. Multivalent antibodies
DK2494356T3 (en) 2009-10-26 2017-05-15 Genentech Inc ASSAYS FOR THE DETECTION OF ANTIBODIES SPECIFIC TO THERAPEUTIC ANTI-IGE ANTIBODIES AND THEIR USE OF ANAPHYLAXY
KR20130100118A (ko) 2010-08-03 2013-09-09 아비에 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
JP6411214B2 (ja) * 2011-11-11 2018-10-24 ユーシービー バイオファルマ エスピーアールエル アルブミン結合抗体及びその結合断片
WO2013116287A1 (en) 2012-01-31 2013-08-08 Genentech, Inc. Anti-ig-e m1' antibodies and methods using same
US20150140608A1 (en) 2012-06-01 2015-05-21 Momenta Pharmaceuticals, Inc. Methods related to omalizumab
JP6136279B2 (ja) 2013-01-15 2017-05-31 株式会社ジェイテクト 転がり軸受装置
TWI503850B (zh) 2013-03-22 2015-10-11 Polytronics Technology Corp 過電流保護元件
US10196458B2 (en) * 2013-07-26 2019-02-05 The Regents Of The University Of California Anti-immunoglobulin E antibodies and methods of using thereof
TWI510996B (zh) 2013-10-03 2015-12-01 Acer Inc 控制觸控面板的方法以及使用該方法的可攜式電腦
CN104987412A (zh) 2015-07-14 2015-10-21 上海拜豪生物科技有限公司 一种砷-IgE螯合物及其制备方法和应用
US20180273626A1 (en) * 2015-09-11 2018-09-27 The Board Of Trustees Of The Leland Stanford Junio University Omalizumab resistant ige variants and their use in anti-ige therapy
GB201610198D0 (en) * 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
US9816280B1 (en) 2016-11-02 2017-11-14 Matthew Reitnauer Portable floor

Also Published As

Publication number Publication date
ZA201807822B (en) 2020-05-27
CA3027120A1 (en) 2017-12-14
EA201990004A1 (ru) 2019-06-28
US12054559B2 (en) 2024-08-06
PE20190212A1 (es) 2019-02-07
IL321493A (en) 2025-08-01
BR112018074838A2 (pt) 2019-03-26
IL263452A (en) 2019-01-31
JP7612641B2 (ja) 2025-01-14
CN109379892A (zh) 2019-02-22
RU2019100034A (ru) 2020-07-13
US20220235146A1 (en) 2022-07-28
US11214627B2 (en) 2022-01-04
KR20190017949A (ko) 2019-02-20
MX2018014761A (es) 2019-04-25
TW201802114A (zh) 2018-01-16
CL2018003556A1 (es) 2019-04-05
US20250011473A1 (en) 2025-01-09
SG11201810199WA (en) 2018-12-28
ZA202000803B (en) 2021-08-25
CN109379892B (zh) 2023-07-04
US20190144565A1 (en) 2019-05-16
EP3468995A1 (en) 2019-04-17
CO2018013006A2 (es) 2019-04-30
IL309516A (en) 2024-02-01
UY37290A (es) 2018-01-31
KR102456813B1 (ko) 2022-10-20
PH12018502574A1 (en) 2019-10-28
RU2019100034A3 (es) 2020-11-20
JP2019522470A (ja) 2019-08-15
UA126468C2 (uk) 2022-10-12
MA45231A (fr) 2021-05-05
JP2023021974A (ja) 2023-02-14
GB201702435D0 (en) 2017-03-29
IL263452B2 (en) 2024-05-01
AU2017277600A1 (en) 2019-01-03
WO2017211928A1 (en) 2017-12-14
IL263452B1 (en) 2024-01-01
JP2025011170A (ja) 2025-01-23
TN2018000423A1 (en) 2020-06-15
AU2017277600B2 (en) 2024-08-29
AU2017277600A2 (en) 2019-01-17
GB201610198D0 (en) 2016-07-27
JP7164439B2 (ja) 2022-11-01
CL2021002696A1 (es) 2022-06-03
AR108707A1 (es) 2018-09-19
IL321493B1 (en) 2026-07-01

Similar Documents

Publication Publication Date Title
CL2021002696A1 (es) Anticuerpos anti-ige (divisional de solicitud 201803556)
JOP20210071A1 (ar) أجسام مضادة مثبّتة trem2
CO2018004090A2 (es) Anticuerpos anti-tigit y métodos de uso
MX2019013132A (es) Anticuerpos que comprenden regiones constantes pesadas modificadas.
MX2018001596A (es) Anticuerpos anti-receptor ccr7 humanizados.
CO2018005932A2 (es) Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas
BR112022000328A2 (pt) Inibidores peptídicos do receptor de interleucina-23 e seu uso para tratar doenças inflamatórias
CL2016003335A1 (es) Diacuerpos enlazados covalentemente que tienen inmunoreactividad con pd-1 y lag-3, y metodos de uso de los mismos
MX386942B (es) Anticuerpos que comprenden regiones constantes pesadas modificadas.
ECSP19029758A (es) Anticuerpos anti-il-33 y usos de los mismos
MX2018014172A (es) Métodos para romper la tolerancia inmunológica usando múltiples arn guías.
BR112018017172A2 (pt) anticorpos monoclonais anti-alfa-sinucleína para prevenção da agregação de tau
MX2019002344A (es) Metodos de prevenir o tratar la alergia administrando un antagonista de il-4r.
CL2021000736A1 (es) Receptor de antígeno quimérico.
WO2014058924A3 (en) Antibodies recognizing alpha-synuclein
WO2020089396A3 (en) Composition and methods of treating inflammatory and autoimmune diseases
BR112013021863A2 (pt) anticorpos anti-receptor il-6 e métodos de uso
SV2010003494A (es) Anticuerpos anti-cxcr5 humanizados, derivados de los mismos y su uso
EA201991511A1 (ru) Кристаллическая структура гремлин-1 и ингибирующее антитело
CL2023003694A1 (es) Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, métodos de uso
AR104250A1 (es) Anticuerpo anti-notch4 humano
BRPI0906478B8 (pt) anticorpo anti-nr10, seu uso e composição farmacêutica que o compreende
MX2018011622A (es) Pirimidinas y sus variantes, y usos de las mismas.
MX2018005589A (es) Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas.
UY37089A (es) Moléculas con uso plaguicida, y sus intermediarios, composiciones y procesos relacionados